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CASE REPORT Open Access
Two successful pregnancies following
fertility preservation in a patient with
anaplastic astrocytoma: a case report
Alexandra Peyser1,2, Sara L. Bristow1 and Avner Hershlag1,2*
Abstract
Background: Astrocytomas are the most common malignant glial tumors. With improved prognosis, it is possible
for patients to pursue pregnancy post-treatment. However, with potential gonadotoxicity of oncology treatments,
fertility preservation prior to chemotherapy and/or radiation therapy should be considered. This requires close
collaboration between the oncologist and reproductive endocrinologist. To our knowledge this is the first report of
successful pregnancies following fertility preservation for AA.
Case presentation: 33-year-old nulligravid woman with newly diagnosed anaplastic astrocytoma (AA; WHO grade
III, IDH1-negative) sought fertility preservation. Prior to chemotherapy and radiation for AA, the patient underwent
in vitro fertilization (IVF) for fertility preservation, resulting in 8 vitrified embryos. Following chemo-radiation, the
patient underwent two rounds of frozen embryo transfers (FET), each resulting in a successful singleton pregnancy.
Conclusion: This case illustrates the realistic possibility, in carefully selected patients with brain tumors, of oocyte or
embryo cryo-preservation prior to chemo-radiation and subsequent pregnancies.
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Background
Astrocytomas are the most common malignant glial tu-
mors originating from small star- shaped glial cells (as-
trocytes) within the central nervous system. Anaplastic
astrocytomas (AA) are defined as grade III glial tumors
according to the WHO 2000 classification [1]. The inci-
dence of AA is approximately 0.48 per 100,000 person/
years. They occur more often in younger adults ages 30–
50 and account for 17% of primary malignant brain tu-
mors [2]. Prognosis in historical studies, which include
both IDH (Isocitrate dehydrogenase)-mutant and IDH-
wild type AAs, ranges from 3 to 5 five-year-survival.
Prognosis is better for a genetically-defined subset of
IDH-mutant tumors, with a median survival closer to
10 years [3]. The mainstay of therapy is surgery followed
by radiotherapy. Multiple protocols, including various
combinations of high dose radiotherapy, chemotherapy,
alternative fraction regimens, heavy particle treatment,
interstitial brachytherapy and radiosurgery have been
proposed to extend survival [3].
Determining the safety of fertility preservation and sub-
sequent pregnancy after treatment of gliomas is difficult
due to the lack of data in the literature. Most studies have
been done in patients where the glioma was diagnosed
during pregnancy; in these cases there have been reports
of changes in the growth of the tumors throughout the
pregnancy [4–8]. Significantly, it seems that the same hor-
mones and growth factors required for fetal development
may also enhance tumor growth [9]. Currently, no guide-
lines exist for the medical management and treatment of
gliomas diagnosed prior to or during pregnancy. There-
fore, it is recommended that women with treated gliomas
who want to pursue pregnancy should be followed by a
high-risk obstetrician as well as a neuro-oncologist and
monitored throughout pregnancy.
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Case presentation
A 33-year-old nulligravid woman with newly diagnosed
AA (WHO grade III, IDH1 negative) presented to our
office for fertility preservation. The patient had under-
gone a craniotomy with complete resection of her right
parietal lobe tumor one month prior, and was scheduled
to start chemotherapy and radiation in the next month.
Her neuro-oncologist recommended that she undergo
fertility preservation prior to chemo-radiation. The fer-
tility preservation did not delay the anticipated start of
her chemo-radiation treatment.
The patient had no significant medical or gynecological
history. On physical exam, the patient was a healthy-
appearing woman. She had left lower extremity weakness
and instability. Transvaginal ultrasound demonstrated a
normal-appearing uterus and ovaries bilaterally. A domin-
ant follicle was noted on her right ovary; therefore, it was
decided to administer HCG 10,000 IU at the time of her
presentation to trigger ovulation, thus enabling the initi-
ation of gonadotropins two weeks later. The patient had a
high antral follicle count (6 on right, 7 on left).
The patient received low dose gonadotropins: 1 am-
pule of Human Menopausal Gonadotropin (Menopur®,
Ferring Pharmaceuticals, Parsippany, NJ, USA), 75–187.
5 IU of FSH (Gonal F®, EMD Serono, Rockland, MA,
USA) for 10 days and cetrorelix acetate (Ganirelex®,
GnRH antagonist, EMD Serono, Rockland, MA, USA)
for the last 6 days. Final oocyte maturation was triggered
with Lupron Luprolide Acetate (Lupron®, GnRH agonist,
SANDOZ Pharmaceuticals, Princeton, NJ, USA) 40u.
Twelve oocytes were retrieved transvaginally under
ultrasound guidance. Eight embryos developed and were
vitrified in liquid nitrogen (6 on day 3 and 2 on day 5
post-retrieval).
The patient returned to our Center one year later after
she was cleared by her neuro-oncologist following the
completion of chemotherapy and radiation. The patient
had 6 weeks of radiation therapy with Temozolomide
(Temodar®, Merck&Co, Inc., Whitehouse Station, NJ,
USA) followed by 6 months of maintenance dose. Her
last dose of chemotherapy was one month prior to
returning to the office. The patient had maintained regu-
lar cycles post chemotherapy. The patient underwent a
frozen-thaw natural cycle embryo transfer of a single
day-3 embryo with vaginal progesterone (Crinone®, Acta-
vis, Parsippany, NJ, USA) luteal phase support. The pa-
tient remained on Keppra® 500 TID (levetiracetam, UCB
Pharmacueticals, Brussels, Belgium) and Lactulose
throughout the pregnancy. A viable singleton pregnancy
was seen on ultrasound 1 month later. The patient deliv-
ered a healthy female baby weighing 7lbs 5 oz. at term.
The patient returned two years later desirous of an-
other pregnancy. Her neurological status had been
stable, was tumor free and was cleared by her oncologist
to conceive again. This time the patient was treated with
Estrace® (estradiol, Warner Chilcott, Rockaway, NJ,
USA) 6 mg a day and underwent a frozen-thaw cycle
with a single day-5 blastocyst transferred. The patient
conceived with a viable singleton pregnancy and deliv-
ered a healthy male at term weighing 6lbs.
Throughout the patient’s treatment regimen for fertil-
ity preservation and frozen embryo transfers, no adverse
or unanticipated events were encountered.
Discussion and conclusions
Women diagnosed with gliomas during child-bearing
years may undergo fertility preservation prior to receiv-
ing chemotherapy and radiation to harvest oocytes and
freeze them or freeze embryos if they have a partner,
since their postoperative treatment, especially chemo-
therapy, is potentially gonadotoxic and may render them
sterile. Studies have shown that the risk of ovarian fail-
ure as a result of chemotherapy varies based on both the
drugs used as well as the patient’s age [10, 11]. Temozo-
lomide (Temodar®, Merck&Co, Inc., Whitehouse Station,
NJ, USA) is an alkylating agent, and while the effects of
other alkylating agents used for chemotherapy on fertil-
ity have been studied, little is published about the gona-
dotoxicity of temozolomide in females. A handful of
small studies have shown that fertility potential is af-
fected in males [12, 13], with one case resulting in fa-
thering a healthy child after treatment with
temozolomide [13]. A study from France followed fertil-
ity outcomes in two groups of glioma survivors who had
received temozolomide categorized based on whether
the patient pursued fertility preservation [14]. They ob-
served one spontaneous pregnancy in a woman who did
not undergo fertility preservation and three pregnancies
– one delivery, one spontaneous miscarriage, and one
ongoing pregnancy – in women that underwent fertility
preservation (four out of 24 women followed for one to
five years). In the absence of more data, we recommend
to assume high gonadotoxicity level of temozolomide,
and pursuing fertility preservation in such patients fol-
lowing clearance by the neuro-oncologist.
A remaining concern for oncologists and oncologic
surgeons is whether fertility preservation delays critical
treatment. In cases when the patient receives adjuvant
therapy, such as the one presented here, there is typically
a sufficient interval between surgery and planned adju-
vant therapy (chemotherapy and/or radiation) to allow
for a short window of opportunity to freeze eggs or em-
bryos without affecting the cancer treatment timeline at
all. In addition, if neoadjuvant therapy is recommended
in other cases, recent advances in reproductive technolo-
gies allows for fertility preservation to be initiated any
time during the menstrual cycle (“random start”). This
allows patient to start an ovulation induction cycle on
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the day she presents to the oncofertility specialist, and it
is expected that the cycle will be no more than 2 weeks.
Thus, fertility preservation should not delay or alter
treatment regimens for cancer patients.
The literature is scarce regarding the possible interac-
tions between gliomas and pregnancy. Changes of the bio-
logical behavior of some tumor subtypes may occur
during pregnancy, such as an accelerated tumor growth
and/or malignant transformation. Several reports have dis-
cussed interactions between pregnancy and the growth of
gliomas. One study analyzed velocity of diametric expan-
sion (VDE) of WHO grade II gliomas in 11 pregnant
women and demonstrated an increase in VDE during
pregnancy [4]. Multiple case series have demonstrated
cases where woman with WHO grade II gliomas devel-
oped de-differentiation of the tumor during pregnancy
which became apparent either clinically, radiologically or
confirmed histologically by post-delivery surgeries [5–7].
A recent case report revealed a malignant transformation
from diffuse astrocytoma (WHO grade II) to glioblastoma
(WHO grade IV) in a post-partum patient 1 month fol-
lowing the patient’s delivery [8].
The mechanism by which tumor growth is enhanced
during pregnancy stems from the idea that the large
amount of hormones and growth factors excreted during
pregnancy simultaneously increase tumor growth. Pla-
cental growth factor for example, is an angiogenic elem-
ent necessary for both fetal development and the growth
of gliomas [9]. Due to the relative paucity of cases re-
ported, the majority of cases focus on gliomas diagnosed
during pregnancy. There are no guidelines for the man-
agement of gliomas diagnosed either during or prior to
pregnancy. If a woman with a treated glioma desires a
pregnancy it is advised to perform very close neuro-
logical follow-up with repeat MRI’s in addition to obstet-
rical monitoring.
The use of antiepileptic drugs (AEDs) during the
course of pregnancy may be teratogenic and increase the
risk of congenital malformations. Levetiracetam (Kep-
pra®) is considered a safe medication for use during
pregnancy. The North American AED pregnancy regis-
try published data collected from pregnant women tak-
ing Levetiracetam monotheraphy from 1997 to 2011.
The relative risk of major malformations was not in-
creased in comparison to women with epilepsy who did
not take AEDs while pregnant [15].
To our knowledge this is the first report of successful
pregnancies following fertility preservation for AA. This
case illustrates the realistic possibility of oocyte or em-
bryo cryo-preservation prior to chemotherapy and radi-
ation with subsequent embryo transfers. A recent article
published in Neuro-Oncology [16], describes a study
reviewing primary brain tumor patients age 18–45, re-
ferred for fertility preservation. Seventy-three percent
accepted referral to a sperm bank (87% men) or a repro-
ductive endocrinologist (56% women). The study con-
cludes that there is significant interest in fertility
preservation among these patients, particularly if they
had no children [16]. Patients should be informed at the
time of tumor diagnosis about the option of preserving
their fertility. Proper referral to a reproductive endocrin-
ologist as well as a mental health professional is recom-
mended to help make informed decisions [17].
It is incumbent upon physicians to engage in discus-
sion of the ethical perspectives of fertility preservation in
patients with brain tumors. For childless women, the op-
tion of post-treatment pregnancy opens a window of
hope that may elevate their mood, helping them cope
with a potentially fatal diagnosis and difficult treatment.
However, the possibility that pregnancy may negatively
affect prognosis remains a major concern.
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